TIGIT gene
iTeos to Shut Down Operations After TIGIT Therapy Setback
iTeos Therapeutics; TIGIT failure; GSK exit; clinical trial failure; belrestotug; asset sale; immuno-oncology; EOS-984; EOS-215; ENT1 obesity program
GSK and iTeos End Belrestotug TIGIT Program After Disappointing Lung Cancer Results
GSK; iTeos; belrestotug; TIGIT; lung cancer; dostarlimab; clinical trial; drug development; GALAXIES Lung-201; immuno-oncology; progression-free survival
Merck Discontinues TIGIT and LAG-3 Programs Amid Efficacy Concerns
Merck, TIGIT, LAG-3, Keytruda, Cancer Therapy, Clinical Trials
Roche’s TIGIT Drug Candidate Tiragolumab Fails to Meet Overall Survival Endpoint in Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, phase 3 trial, SKYSCRAPER-01, overall survival, Keytruda, Tecentriq
Arcus Biosciences Reveals Positive Data from Terminated TIGIT Combo Trial, Supporting Future Development
Arcus Biosciences, TIGIT combo, domvanalimab, zimberelimab, cancer treatment, clinical trials
iTeos-GSK’s TIGIT Combination Demonstrates Superior Tumor Shrinkage in Phase 2 Trial
iTeos Therapeutics, GSK, TIGIT, EOS-448, Jemperli, Phase 2 trial, tumor shrinkage, immuno-oncology, cancer treatment
Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus
Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal
Roche’s TIGIT Drug Tiragolumab Fails Another Phase 3 Lung Cancer Trial
Roche, TIGIT, tiragolumab, lung cancer, Phase 3 trial, failure, Keytruda, Tecentriq
Merck Pauses Phase 3 TIGIT Trial Due to Immune-Mediated Adverse Events
Merck, Phase 3 Trial, TIGIT, Immune-mediated Adverse Events, Discontinuations